Oral compositions delivering therapeutically effective amounts of cannabinoids

Abstract

Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject.

What is claimed is: 
     
         1 . A method of preventing or treating diseases or disorders associated with abnormal mitogen-activated protein (MAP) kinase activity or levels in a subject, comprising:
 administering to the subject a composition comprising: a cannabinoid, a blend of cannabinoids, a sugar, sugar blend, sugar alcohol, a blend of sugar alcohols, a gum base, and combinations thereof; thereby,   preventing or treating diseases or disorders associated with abnormal mitogen-activated protein (MAP) kinase activity or levels in the subject.   
     
     
         2 . The method of  claim 1 , wherein the composition, based on the total weight of the composition, comprises:
 about 0.1% to about 20% by weight of cannabinoids,   about 10% to about 80% by weight of a sugar, sugar blend, sugar alcohol, or a blend of sugar alcohols, or combinations thereof,   about 5% to about 80% of a gum base.   
     
     
         3 . The method of  claim 1 , further comprising: flavoring, tableting lubricants and powder flow agents, intensive sweeteners, sugar substitutes and combinations thereof. 
     
     
         4 . The method of  claim 1 , wherein the composition, based on the total weight of the composition, further comprises:
 about 1% to about 20% by weight of flavoring,   about 0.1% to about 10% by weight of tableting lubricants and powder flow agents,   about 0.01% to about 2% by weight of intensive sweeteners.   
     
     
         5 . The method of  claim 1 , a cannabinoid or derivatives thereof, comprises about 0.1% to about 80% by weight, based on total weight of the cannabinoids. 
     
     
         6 . The method of  claim 5 , wherein cannabinoids comprise about 0.1% to about 15% by weight. 
     
     
         7 . The method of  claim 1 , wherein the sugar or sugar blend comprise dextrose, sucrose, fructose, glucose or combinations thereof. 
     
     
         8 . The method of  claim 1 , wherein a disease or disorder associated with abnormal mitogen-activated protein (MAP) kinase activity or levels comprises: neuroinflammatory diseases or disorders, migraines, epilepsy, neuropathic pain, general pain, joint pain, head trauma or combinations thereof. 
     
     
         9 . The method of  claim 1 , wherein the composition increases the expression of MAP kinase phosphatases (MKPs) in vivo or in vitro. 
     
     
         10 . The method of  claim 9 , wherein the MKPs downregulate MAP expression or activity in vivo or in vitro. 
     
     
         11 . A method of preventing or treating diseases or disorders associated with abnormal or increased mitogen-activated protein (MAP) kinase activity or levels in a subject, comprising:
 administering to a subject in need thereof, a gum-based composition for chewing, the composition comprising, based on the total weight of the composition:   about 0.1% to about 20% by weight of a cannabinoid or derivatives thereof,   about 10% to about 80% by weight of a sugar, sugar blend, sugar alcohol, or a blend of sugar alcohols, or combinations thereof,   about 5% to about 80% of a gum base.   about 1% to about 20% by weight of flavoring,   about 0.1% to about 10% by weight of tableting lubricants and powder flow agents,   about 0.01% to about 2% by weight of intensive sweeteners, and combinations thereof.   
     
     
         12 . The method of  claim 11 , wherein the composition is in a gum or tablet form. 
     
     
         13 . The method of  claim 11 , wherein a disease or disorder associated with abnormal mitogen-activated protein (MAP) kinase activity or levels comprises: neuroinflammatory diseases or disorders, migraines, epilepsy, neuropathic pain, general pain, joint pain, head trauma or combinations thereof. 
     
     
         14 . The method of  claim 11 , wherein the composition increases the expression of MAP kinase phosphatases (MKPs) in vivo or in vitro. 
     
     
         15 . The method of  claim 14 , wherein the MKPs downregulate MAP expression or activity in vivo or in vitro. 
     
     
         16 . A method of preventing or treating diseases or disorders associated with abnormal mitogen-activated protein (MAP) kinase activity or levels in a subject, comprising:
 administering to the subject a composition comprising: a sugar, a sugar blend, sugar alcohol, a blend of sugar alcohols, sweeteners, a bulk filler, a cannabinoid, flavorings, tableting lubricants, powder flow agents and combinations thereof.   
     
     
         17 . The method of  claim 16 , wherein the composition, based on the total weight of the composition, comprises:
 about 10% to about 80% by weight of a sugar, a sugar blend, sugar alcohol, blend of sugar alcohols, sweetener and combinations thereof,   about 5% to about 50% by weight of bulk filler,   about 0.1% to about 20% by weight of a cannabinoid or derivatives thereof,   about 0.1% to about 10% by weight of flavorings,   about 0.1% to about 10% by weight of tableting lubricants and powder flow agents, and combinations thereof.   
     
     
         18 . The method of  claim 16 , wherein the composition, based on the total weight of the composition, comprises:
 about 55% to about 70% by weight of a sugar, a sugar blend, sugar alcohol, blend of sugar alcohols, sweetener and combinations thereof,   about 5% to about 40% by weight of bulk filler,   about 0.1% to about 10% by weight of a cannabinoid or derivatives thereof,   about 0.1% to about 5% by weight of flavorings,   about 0.1% to about 5% by weight of tableting lubricants and powder flow agents, and combinations thereof.   
     
     
         19 . The method of  claim 16 , wherein the sugar or sugar blend comprise dextrose, sucrose, fructose, glucose and combinations thereof. 
     
     
         20 . The method of  claim 16 , wherein the sugar alcohol or sugar alcohol blend comprise: sorbitol, isomalt, xylitol, maltitol, mannitol, erythritol and combinations thereof. 
     
     
         21 . The method of  claim 16 , wherein the sweetener comprises sucralose, monk fruit, neotame, licorice extract, stevia, honey or agave nectar and combinations thereof. 
     
     
         22 . The method of  claim 16 , wherein the tableting lubricants and powder flow agents comprises magnesium stearate, silicon dioxide, calcium stearate, stearic acid, talc, rice bran-based excipients and combinations thereof. 
     
     
         23 . The method of  claim 16 , wherein a bulk filler comprises microcrystalline cellulose (MCC), bamboo fibers and combinations thereof. 
     
     
         24 . The method of  claim 16 , wherein a disease or disorder associated with abnormal mitogen-activated protein (MAP) kinase activity or levels comprises: neuroinflammatory diseases or disorders, migraines, epilepsy, neuropathic pain, general pain, joint pain, head trauma or combinations thereof. 
     
     
         25 . The method of  claim 16 , wherein the composition increases the expression of MAP kinase phosphatases (MKPs) in vivo or in vitro. 
     
     
         26 . The method of  claim 25 , wherein the MKPs downregulate MAP expression or activity in vivo or in vitro. 
     
     
         27 . A method of preventing or treating diseases or disorders associated with abnormal mitogen-activated protein (MAP) kinase activity or levels in a subject, comprising:
 administering to the subject composition comprising a sugar, a sugar blend, sugar alcohol, a blend of sugar alcohols, sweeteners, a bulk filler, a cannabidiol (CBD), tetrahydrocannabinol (THC), flavorings, tableting lubricants, powder flow agents, and combinations thereof thereby,   preventing or treating diseases or disorders associated with abnormal MAP kinase activity or levels in a subject.   
     
     
         28 . The method of  claim 27 , wherein the composition, based on the total weight of the composition, comprises:
 about 10% to about 80% by weight of a sugar, a sugar blend, sugar alcohol, blend of sugar alcohols, sweetener, or combinations thereof,   about 5% to about 50% by weight of bulk filler,   about 0.1% to about 20% by weight of a cannabidiol (CBD), a tetrahydrocannabinol (THC) and combinations thereof,   about 0.1% to about 10% by weight of a flavoring,   about 0.1% to about 10% by weight of tableting lubricants and powder flow agents, and combinations thereof.   
     
     
         29 . The method of  claim 27 , wherein the composition, based on the total weight of the composition, comprises:
 about 55% to about 70% by weight of a sugar, a sugar blend, sugar alcohol, blend of sugar alcohols, sweetener, or combinations thereof,   about 5% to about 40% by weight of bulk filler,   about 0.1% to about 10% by weight of a cannabinoid or derivatives thereof,   about 0.1% to about 5% by weight of flavorings,   about 0.1% to about 5% by weight of tableting lubricants and powder flow agents, and combinations thereof.   
     
     
         30 . The method of  claim 27 , wherein the sugar or sugar blend comprise dextrose, sucrose, fructose, glucose or combinations thereof. 
     
     
         31 . The method of  claim 27 , wherein the sugar alcohol or sugar alcohol blend comprise: sorbitol, isomalt, xylitol, maltitol, mannitol, erythritol or combinations thereof. 
     
     
         32 . The method of  claim 27 , wherein the sweetener comprises sucralose, monk fruit, neotame, aspartame, acesulfame potassium, licorice extract, stevia, honey or agave nectar, or combinations thereof. 
     
     
         33 . The method of  claim 27 , wherein the tableting lubricants and powder flow agents comprises magnesium stearate, silicon dioxide, calcium stearate, stearic acid, talc, rice bran-based excipients, or combinations thereof. 
     
     
         34 . The method of  claim 27 , wherein a bulk filler comprises microcrystalline cellulose (MCC), bamboo fibers, or combinations thereof.